One of the major aims of stroke physicians is to save as much brain as possible after a stroke, allowing the patient to potentially regain major functionality. After the introduction of thrombolysis substantially improved the outcome for ischemic stroke patients, there was high hope that so-called neuroprotective agents would further improve outcomes after stroke. These agents directly or indirectly reduce the damage resulting from brain ischemia. However, individual trials of neuroprotective agents in acute ischemic stroke have been persistently disappointing. Efforts to pool results from several randomized trials have been undertaken to increase the statistical power to observe beneficial effects of neuroprotective agents. One such effort recently has been published for the neuroprotective agent citicoline. The Ferrer Group, a producer of citicoline, funded the study by Casado et al.